MXPA05006790A - Usos de antagonistas del receptor adenosina a2a. - Google Patents
Usos de antagonistas del receptor adenosina a2a.Info
- Publication number
- MXPA05006790A MXPA05006790A MXPA05006790A MXPA05006790A MXPA05006790A MX PA05006790 A MXPA05006790 A MX PA05006790A MX PA05006790 A MXPA05006790 A MX PA05006790A MX PA05006790 A MXPA05006790 A MX PA05006790A MX PA05006790 A MXPA05006790 A MX PA05006790A
- Authority
- MX
- Mexico
- Prior art keywords
- adenosine
- receptor antagonists
- plms
- rls
- dystonia
- Prior art date
Links
- 229940123702 Adenosine A2a receptor antagonist Drugs 0.000 title abstract 2
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 title abstract 2
- 208000027776 Extrapyramidal disease Diseases 0.000 abstract 3
- 208000005793 Restless legs syndrome Diseases 0.000 abstract 3
- 208000014094 Dystonic disease Diseases 0.000 abstract 2
- 208000010118 dystonia Diseases 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000737 periodic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Se describe un metodo para el tratamiento o prevencion del Sindrome extrapiramidal (EPS), distonia, sindrome de piernas inquietas (RLS) o movimiento periodico de extremidades durante el sueno (PLMS), que comprende la administracion de un antagonista del receptor de adenosina A2a, solo o en combinacion con otros agentes utiles para el tratamiento de EPS, distonia, RLS o PLMS.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US43532102P | 2002-12-19 | 2002-12-19 | |
PCT/US2003/040456 WO2005044245A1 (en) | 2002-12-19 | 2003-12-17 | USES OF ADENOSINE A2a RECEPTOR ANTAGONISTS |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA05006790A true MXPA05006790A (es) | 2005-09-08 |
Family
ID=34572685
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA05006790A MXPA05006790A (es) | 2002-12-19 | 2003-12-17 | Usos de antagonistas del receptor adenosina a2a. |
Country Status (16)
Country | Link |
---|---|
US (2) | US7414058B2 (es) |
EP (3) | EP1578409B1 (es) |
JP (3) | JP2006514697A (es) |
CN (2) | CN100415217C (es) |
AT (1) | ATE490775T1 (es) |
AU (2) | AU2003304527B2 (es) |
BR (1) | BR0317436A (es) |
DE (1) | DE60335294D1 (es) |
ES (1) | ES2354875T3 (es) |
HK (1) | HK1074585A1 (es) |
MX (1) | MXPA05006790A (es) |
NO (1) | NO20053509L (es) |
NZ (1) | NZ540493A (es) |
TW (1) | TWI331036B (es) |
WO (1) | WO2005044245A1 (es) |
ZA (1) | ZA200504478B (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100384847C (zh) * | 2000-05-26 | 2008-04-30 | 先灵公司 | 腺苷A2a受体拮抗剂 |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
ES2354875T3 (es) * | 2002-12-19 | 2011-03-18 | Schering Corporation | Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal. |
US20060128694A1 (en) * | 2002-12-19 | 2006-06-15 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
US20060106040A1 (en) * | 2002-12-19 | 2006-05-18 | Michael Grzelak | Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders |
ES2326270T3 (es) * | 2003-04-23 | 2009-10-06 | Schering Corporation | Antagonistas del receptor de la adenosina a2a 2-alquinil- y 2-alquenil-pirazolo-(4,3-e)-1,2,4-triazolo-(1,5-c)-pirimidina. |
NZ527142A (en) * | 2003-07-23 | 2006-03-31 | Douglas Pharmaceuticals Ltd | A stable suspension formulation |
AU2005236059B2 (en) * | 2004-04-21 | 2009-01-15 | Schering Corporation | Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists |
EP1794157B1 (en) | 2004-09-22 | 2014-02-26 | H. Lundbeck A/S | 2-acylaminothiazole derivatives |
US8455437B2 (en) * | 2005-02-04 | 2013-06-04 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Method to predict and prevent oxygen-induced inflammatory tissue injury |
US7674912B2 (en) * | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
ATE556712T1 (de) * | 2005-06-07 | 2012-05-15 | Kyowa Hakko Kirin Co Ltd | A2a antagonisten zur behandlung von motorischen störungen |
AR057817A1 (es) * | 2005-09-19 | 2007-12-19 | Schering Corp | Antagonistas del receptor a2a de 2-heteroaril-pirazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pirimidin adenosina. composiciones farmaceuticas |
PE20070521A1 (es) | 2005-09-23 | 2007-07-13 | Schering Corp | 7-[2-[4-(6-FLUORO-3-METIL-1,2-BENCISOXAZOL-5-IL)-1-PIPERAZINIL]ETIL]-2-(1-PROPINIL)-7H-PIRAZOL-[4,3-E]-[1,2,4]-TRIAZOL-[1,5-C]-PIRIMIDIN-5-AMINA COMO ANTAGONISTA DEL RECEPTOR DE ADENOSINA A2a |
ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
CA2717172A1 (en) | 2008-03-04 | 2009-09-11 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo [4,3-e] -1,2,4-triazolo [4,3-c] pyrimidin-3-one compounds for use as adenosine a2a receptor antagonists |
TWI473614B (zh) * | 2008-05-29 | 2015-02-21 | Kyowa Hakko Kirin Co Ltd | Anti-analgesic inhibitors |
CN102438624B (zh) | 2009-03-13 | 2016-03-30 | 阿德维纳斯治疗私人有限公司 | 取代的稠合嘧啶化合物 |
JP5843778B2 (ja) | 2009-11-09 | 2016-01-13 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物、その調製およびその使用 |
EP2509983B1 (en) | 2009-11-16 | 2014-09-17 | Merck Sharp & Dohme Corp. | FUSED TRICYCLIC COMPOUNDS WITH ADENOSINE A2a RECEPTOR ANTAGONIST ACTIVITY |
US8473582B2 (en) * | 2009-12-16 | 2013-06-25 | International Business Machines Corporation | Disconnected file operations in a scalable multi-node file system cache for a remote cluster file system |
WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
MX352415B (es) | 2010-02-05 | 2017-11-22 | Heptares Therapeutics Ltd Star | Derivados de 1, 2, 4-triazin-4-amina. |
CA2812378C (en) * | 2010-09-24 | 2016-11-29 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
WO2014101113A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Piperazine-substituted 7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
CN105025899B (zh) * | 2012-12-28 | 2017-08-18 | 默沙东公司 | 具有A2A拮抗剂性质的杂二环取代的‑[1,2,4]三唑并[1,5‑c]喹唑啉‑5‑胺化合物 |
WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
WO2018013951A1 (en) * | 2016-07-15 | 2018-01-18 | Northwestern University | Targeting adenosine a2a receptors for the treatment of levodopa-induced dyskinesias |
WO2019002606A1 (en) * | 2017-06-30 | 2019-01-03 | Selvita S.A. | ADENOSINE A2A RECEPTOR 5,6-BICYCLO-IMIDAZO [1,2-A] PYRAZINE MODULATORS |
WO2019123482A1 (en) | 2017-12-19 | 2019-06-27 | Impetis Biosciences Ltd. | Pharmaceutical composition for the treatment of cancer |
AU2019205661B2 (en) * | 2018-01-04 | 2022-06-30 | Impetis Biosciences Ltd. | Tricyclic compounds, compositions and medicinal applications thereof |
DE102019116986A1 (de) | 2019-06-24 | 2020-12-24 | Helmholtz-Zentrum Dresden-Rossendorf E. V. | Deuterierte 7-(3-(4-(2-([18F]Fluor)ethoxy)phenyl)propyl)-2-(furan-2-yl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amin-Derivate |
EP3999513A4 (en) * | 2019-07-17 | 2022-12-21 | Teon Therapeutics, Inc. | ADENOSINE A2A RECEPTOR ANTAGONISTS AND THEIR USES |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1264901B1 (it) | 1993-06-29 | 1996-10-17 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina |
US5565460A (en) | 1993-07-27 | 1996-10-15 | Kyowa Hakko Koygo Co., Ltd. | Therapeutic purine agents for parkinson's disease |
IT1277392B1 (it) * | 1995-07-28 | 1997-11-10 | Schering Plough S P A | Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina |
US5933964A (en) * | 1996-07-17 | 1999-08-10 | Wahl Clipper Corporation | Cutter blade for hair clippers |
EP0975345A1 (en) | 1997-11-26 | 2000-02-02 | Cerebrus Pharmaceuticals Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
GB9915437D0 (en) * | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
CN100384847C (zh) * | 2000-05-26 | 2008-04-30 | 先灵公司 | 腺苷A2a受体拮抗剂 |
GB0100624D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
ATE424194T1 (de) * | 2001-04-09 | 2009-03-15 | Neurosearch As | Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson |
MXPA04002389A (es) * | 2001-09-13 | 2004-05-31 | Schering Corp | Combinacion de un antagonista del receptor de adenosian a2a y un antidepresivo o ansiolitico. |
CA2463598C (en) | 2001-10-15 | 2009-09-08 | Schering Corporation | Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists |
AR038366A1 (es) | 2001-11-30 | 2005-01-12 | Schering Corp | Compuestos de 1,2,4-triazolo [1,5-c] pirimidinas sustituidas, antagonistas del receptor de adenosina a2a, composiciones farmaceuticas, el uso de dichos compuestos para la manufactura de un medicamento para el tratamiento de enfermedades del sistema nervioso central y un kit que comprende combinacion |
KR20050044593A (ko) | 2001-11-30 | 2005-05-12 | 쉐링 코포레이션 | 아데노신 A2a 수용체 길항제 |
DE60219196T2 (de) * | 2001-11-30 | 2008-01-03 | Schering Corp. | BICYCLISCHE [1,2,4]-TRIAZOL ADENOSIN A2a REZEPTOR ANTAGONISTEN |
JP4376630B2 (ja) | 2002-01-28 | 2009-12-02 | 協和発酵キリン株式会社 | 運動障害治療剤 |
ATE400275T1 (de) * | 2002-08-30 | 2008-07-15 | Kyowa Hakko Kogyo Kk | Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus |
ES2354875T3 (es) * | 2002-12-19 | 2011-03-18 | Schering Corporation | Uso de antagonistas del receptor a2a de la adenosina para el tratamiento o prevención del síndrome extrapiramidal. |
ES2326270T3 (es) * | 2003-04-23 | 2009-10-06 | Schering Corporation | Antagonistas del receptor de la adenosina a2a 2-alquinil- y 2-alquenil-pirazolo-(4,3-e)-1,2,4-triazolo-(1,5-c)-pirimidina. |
-
2003
- 2003-12-17 ES ES03818838T patent/ES2354875T3/es not_active Expired - Lifetime
- 2003-12-17 JP JP2005510511A patent/JP2006514697A/ja not_active Withdrawn
- 2003-12-17 DE DE60335294T patent/DE60335294D1/de not_active Expired - Lifetime
- 2003-12-17 WO PCT/US2003/040456 patent/WO2005044245A1/en active Application Filing
- 2003-12-17 TW TW092135740A patent/TWI331036B/zh not_active IP Right Cessation
- 2003-12-17 AT AT03818838T patent/ATE490775T1/de not_active IP Right Cessation
- 2003-12-17 AU AU2003304527A patent/AU2003304527B2/en not_active Ceased
- 2003-12-17 US US10/738,906 patent/US7414058B2/en not_active Expired - Fee Related
- 2003-12-17 BR BR0317436-0A patent/BR0317436A/pt not_active IP Right Cessation
- 2003-12-17 CN CNB2003801070872A patent/CN100415217C/zh not_active Expired - Fee Related
- 2003-12-17 EP EP03818838A patent/EP1578409B1/en not_active Expired - Lifetime
- 2003-12-17 EP EP10186087A patent/EP2269596A3/en not_active Withdrawn
- 2003-12-17 CN CNA2008101361548A patent/CN101310724A/zh active Pending
- 2003-12-17 EP EP10186097A patent/EP2295047A3/en not_active Withdrawn
- 2003-12-17 NZ NZ540493A patent/NZ540493A/en not_active IP Right Cessation
- 2003-12-17 MX MXPA05006790A patent/MXPA05006790A/es active IP Right Grant
-
2005
- 2005-05-31 ZA ZA200504478A patent/ZA200504478B/en unknown
- 2005-07-18 NO NO20053509A patent/NO20053509L/no not_active Application Discontinuation
- 2005-09-28 HK HK05108564.4A patent/HK1074585A1/xx not_active IP Right Cessation
-
2008
- 2008-07-29 US US12/181,736 patent/US20090029967A1/en not_active Abandoned
-
2010
- 2010-08-06 JP JP2010177518A patent/JP2011006431A/ja active Pending
- 2010-08-31 AU AU2010214749A patent/AU2010214749B2/en not_active Ceased
-
2013
- 2013-01-29 JP JP2013013961A patent/JP2013136592A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ATE490775T1 (de) | 2010-12-15 |
CN101310724A (zh) | 2008-11-26 |
HK1074585A1 (en) | 2005-11-18 |
EP2295047A3 (en) | 2011-05-18 |
DE60335294D1 (de) | 2011-01-20 |
TW200505927A (en) | 2005-02-16 |
ES2354875T3 (es) | 2011-03-18 |
EP1578409A1 (en) | 2005-09-28 |
CN1728990A (zh) | 2006-02-01 |
AU2003304527A1 (en) | 2005-05-26 |
CN100415217C (zh) | 2008-09-03 |
NO20053509D0 (no) | 2005-07-18 |
EP1578409B1 (en) | 2010-12-08 |
US20040138235A1 (en) | 2004-07-15 |
NZ540493A (en) | 2008-04-30 |
ZA200504478B (en) | 2006-02-22 |
BR0317436A (pt) | 2005-11-16 |
TWI331036B (en) | 2010-10-01 |
US20090029967A1 (en) | 2009-01-29 |
EP2295047A2 (en) | 2011-03-16 |
EP2269596A3 (en) | 2011-09-14 |
AU2003304527B2 (en) | 2010-09-09 |
JP2006514697A (ja) | 2006-05-11 |
NO20053509L (no) | 2005-09-16 |
WO2005044245A1 (en) | 2005-05-19 |
JP2013136592A (ja) | 2013-07-11 |
EP2269596A2 (en) | 2011-01-05 |
US7414058B2 (en) | 2008-08-19 |
AU2010214749A1 (en) | 2010-09-23 |
AU2010214749B2 (en) | 2011-06-09 |
JP2011006431A (ja) | 2011-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA05006790A (es) | Usos de antagonistas del receptor adenosina a2a. | |
HK1049284A1 (en) | Benzimidazole compounds having nociceptin receptoraffinity | |
WO2001013903A3 (de) | Behandlung des restless leg syndroms mit einer kombination von clonidin und opioid | |
HUE043353T2 (hu) | A2A receptor antagonisták mozgás zavarok kezelésében történõ alkalmazásra | |
AP2005003212A0 (en) | Modified 2' and 3' nucleoside prodrugs for treating flaviviridae infections. | |
MXPA03003912A (es) | Tratamientos nuevos para el sindrome de piernas inquietas. | |
MXPA04001525A (es) | Analogos de peptido -1 similar al glucagon. | |
HRP20041180A2 (en) | 11-beta-hidroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia | |
AP2004003161A0 (en) | Substituted benzazoles and use thereof as raf kinase inhibitors. | |
MY137350A (en) | Glucagon-like peptide-1 analogs | |
EP1482912A4 (en) | Naltrexone hydrochloride COMPOSITIONS | |
PL375647A1 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | |
HK1088304A1 (en) | Pyrimidinone derivatives as therapeutic agents against acute and chronic inflammatory, ischaemic and remodelling processes | |
IL176758A0 (en) | 1,3-dioxane derivatives and analogues thereof useful in the treatment of i.a. obesity and diabetes | |
EP1515725A4 (en) | USE OF CYCLOTHIOCARBAMATE DERIVATIVES IN THE TREATMENT OF HORMONE-RELATED ILLNESSES | |
IL165395A0 (en) | Use of thio-oxubdile derivatives in treatment of hormone-related conditions | |
EP1552769A4 (en) | RECLINER DEVICE AND METHOD OF LATCHING SAID DEVICE | |
DE60231386D1 (de) | Adenosin-a2a-rezeptor-antagonisten in kombination mit verbindungen mit neurotrophischer aktivität bei der behandlung von morbus parkinson | |
MXPA04002636A (es) | Barra de tocador teniendo un acidificador latente. | |
NO20082175L (no) | Adenosin A2A-reseptorantagonister for behandling av ekstrapyramidalt syndrom og andre bevegelsesforstyrrelser | |
GB0312425D0 (en) | Use of a compound in the treatment of sleep disorders and the like,in providing refreshedness on waking and a method for the treatment of grogginess therewith | |
PL374077A1 (en) | Use of 5-ht2 receptor antagonists for the treatment of sleep disorders | |
ATA205399A (de) | Möbelstück, welches durch einen aufblasbaren körper gebildet ist | |
TW557773U (en) | Pillow for good sleep | |
ZA200409837B (en) | Device to prevent rocking of tables. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |